

A novel target for development of a new T-cell specific immunosuppressant

CaMKIV plays an important role in T cell activation and is an important target for immunosuppressive agents. The present invention relates to Ca²⁺/calmodulin-dependent protein kinase IV (CaMKIV) and, in particular, to methods of screening compounds for their ability to act as CaMKIV agonists or antagonists. The invention further relates to compounds identified using such methods and to therapeutic methodologies based on same. Agents identified using the screen provided there are T cell specific and thus substantially free of adverse side effects.

Patents

Patent Number: 7,105,312

Title: CA²⁺/Calmodulin-Dependent Protein Kinase IV

Country: United States of America

Duke

LICENSING & VENTURES

 **Duke File (IDF) #**

T-001381

 **Inventor(s)**

- Means, Anthony
- Anderson, Kristin
- Ribar, Thomas

 **College**

School of Medicine (SOM)

**For more information
please contact**

Ferguson, Christy

919-681-7581

christy.ferguson@duke.edu